MaxCyte is a global, clinical-stage, cell-based therapy and life sciences company. As the inventors of the industry standard, non-viral cell-engineering technology, the Company helps bring the potential of next-generation cell and gene-editing therapies to life. The Company’s technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 100 cell therapy programmes, with more than 70 licensed for clinical use, and the Company has now entered into ten clinical/commercial license agreements with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit


Tom Burt

Tom joined Sofinnova in June 2017 from Peel Hunt where he is senior research analyst in Healthcare & Life Sciences. Tom has 11 years of experience in life sciences venture and private company investing, equity and alternative financing (hybrid and debt instruments). He has worked for several years with ...